Infliximab biosimilar (Pfizer)

英夫利昔单抗生物类似药（辉瑞）

Report date: 2022/03/10 20:00:32

Base Information

Drug NameInfliximab biosimilar (Pfizer)
Drug Alias Name英夫利昔单抗生物类似药Infliximab-qbtx英夫利昔单抗生物仿制药IxifiZessly +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[9] 
Global Approved IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2013/09/09
Country/TerritoryUnited StatesEUJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncNovartis Pharma AgPfizer Europe Ma Eeig
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A